What it sells
B2B commerce, payments/settlement and embedded credit platform for pharma retailers and distributors.
Business model breakdown
Buyer: who owns the budget?
Owners of pharma retail shops, distributors and brands in India (15K+ retailers claimed).
Trigger: what makes them buy now?
Working capital gaps and credit access friction when buying medicines.
Workflow: what inputs become what output?
Browse and order on FundlyMart app; pay with unsecured working-capital credit; repay with interest only for days funds are used.
Economics: what it saves and how it charges
Interest on credit (charged only for period used) plus likely commerce/payment margins; rates not disclosed.
Distribution: how it reaches customers
App downloads (iOS/Android) via FundlyMart marketplace; B2B ties with distributors and brands; contact by email/phone.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-08 | Series A | $4 million equity + $0.9 million venture debt | Accel (lead), Multiply Ventures, Rajeev Ahuja, angel investors | entrackr.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.